RxDoctor Payments Data

Barry Glasser, MD

Internal Medicine · Brigantine, NJNPI 1487689162

Payments from drug & device makers

$26,694in general payments, 2019–2025

Across 79 payments — averaging $337.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$19K
  • Biodelivery Sciences International, Inc.$8K
  • Novo Nordisk$237
  • QOL Medical, LLC$105
  • Pfizer$88
  • Lilly USA, LLC$64
  • plus $162 from 9 others

What the payments were for

  • Consulting fees$7403%
  • Speaking & faculty fees$23,99090%
  • Travel & lodging$3751%
  • Food & beverage$1,5896%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,694 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$56,050
Medicare patients
219
Services billed
474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin32$36,169
EliquisApixaban25$34,519
BelbucaBuprenorphine Hcl35$33,019
OzempicSemaglutide20$20,913
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl107$14,454
TradjentaLinagliptin19$10,734
Breo ElliptaFluticasone/Vilanterol15$5,852
Atorvastatin Calcium217$3,797
Rosuvastatin Calcium82$3,090
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen82$2,406
Metformin Hcl200$1,953
Albuterol Sulfate HfaAlbuterol Sulfate56$1,690
Buprenorphine11$1,514
Omeprazole83$1,400
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$34,51925 claims
Collegium Pharmaceutical, Inc.Belbuca$15$33,01935 claims
Novo NordiskOzempic$237$20,91320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Brigantine

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →